Fecal Occult Blood Screening Increases High-Risk Polyp Detection
By LabMedica International staff writers Posted on 12 Jan 2015 |

Image: Biopsy slide of a classic tubular adenoma polyp that is precancerous (Photo courtesy of Dr. Scot M. Lewey).
The introduction of biennial colorectal cancer screening in a region of France increased the rate of diagnosis of high risk precancerous adenomas, sometimes called polyps, by 89%.
As part of the screening program, a prescreening procedure is undertaken by a general practitioner or gastroenterologist to identify patients who are at higher than average risk of colorectal cancer based on their family history and those patients were invited to undergo colonoscopy rather than fecal occult blood test (FOBT).
Scientists at the University of Burgundy (INSERM Unité 866; Dijon, France) evaluate the rate of diagnosis of adenomas before and after the initiation of a screening program using fecal occult blood testing that began in 2003. The study included all residents aged between 50 and 74 years of age who had a first adenoma identified between January 1997 and December 2008. The investigators showed that 38.7% of these people had high-risk adenomas, meaning they were larger than one centimeter in diameter, involved the finger-like projections called villi in the intestinal lining, or exhibited a high grade of dysplasia.
Of 1,179 patients studied, 889 underwent colonoscopy, and overall, 253 colorectal neoplasias were diagnosed including 35 cancers, and adenomas in 219 patients. A total of 209 advanced adenomas were diagnosed. The authors calculated that the positive predictive value of colonoscopy was 3.9% for cancer, 12.9% for advanced adenoma, and 25% for adenoma overall. This compared poorly to the positive predictive value in the average risk population selected by a positive FOBT. In this population, the positive predictive value of the colonoscopy done after positive test in their administrative area ranges from 7.5% to 10% for cancer, from 15% to 27% for advanced adenoma and between 32% and 37% for adenoma. The immunochemical fecal occult blood tests outperformed guaiac tests for the detection of colorectal cancer and advanced adenoma. They have doubled the detection rate of invasive colorectal cancer, mostly at early stages, and led to a fourfold increase in the detection rate of noninvasive colorectal cancer and advanced adenomas.
Hans-Joachim Schmoll, MD, PhD, a professor of Hematology and Oncology, at the Martin Luther University Halle-Wittenberg (Halle, Germany) said, “In this study it was shown that a prediction for screening colonoscopy using high risk features—based on family history—revealed a less positive predictive value than prescreening by FOBT with follow-up of those who have a positive result.” The study was presented at the European Society for Medical Oncology Congress held September 26–30, 2014, in Madrid (Spain).
Related Links:
University of Burgundy
Martin Luther University Halle-Wittenberg
As part of the screening program, a prescreening procedure is undertaken by a general practitioner or gastroenterologist to identify patients who are at higher than average risk of colorectal cancer based on their family history and those patients were invited to undergo colonoscopy rather than fecal occult blood test (FOBT).
Scientists at the University of Burgundy (INSERM Unité 866; Dijon, France) evaluate the rate of diagnosis of adenomas before and after the initiation of a screening program using fecal occult blood testing that began in 2003. The study included all residents aged between 50 and 74 years of age who had a first adenoma identified between January 1997 and December 2008. The investigators showed that 38.7% of these people had high-risk adenomas, meaning they were larger than one centimeter in diameter, involved the finger-like projections called villi in the intestinal lining, or exhibited a high grade of dysplasia.
Of 1,179 patients studied, 889 underwent colonoscopy, and overall, 253 colorectal neoplasias were diagnosed including 35 cancers, and adenomas in 219 patients. A total of 209 advanced adenomas were diagnosed. The authors calculated that the positive predictive value of colonoscopy was 3.9% for cancer, 12.9% for advanced adenoma, and 25% for adenoma overall. This compared poorly to the positive predictive value in the average risk population selected by a positive FOBT. In this population, the positive predictive value of the colonoscopy done after positive test in their administrative area ranges from 7.5% to 10% for cancer, from 15% to 27% for advanced adenoma and between 32% and 37% for adenoma. The immunochemical fecal occult blood tests outperformed guaiac tests for the detection of colorectal cancer and advanced adenoma. They have doubled the detection rate of invasive colorectal cancer, mostly at early stages, and led to a fourfold increase in the detection rate of noninvasive colorectal cancer and advanced adenomas.
Hans-Joachim Schmoll, MD, PhD, a professor of Hematology and Oncology, at the Martin Luther University Halle-Wittenberg (Halle, Germany) said, “In this study it was shown that a prediction for screening colonoscopy using high risk features—based on family history—revealed a less positive predictive value than prescreening by FOBT with follow-up of those who have a positive result.” The study was presented at the European Society for Medical Oncology Congress held September 26–30, 2014, in Madrid (Spain).
Related Links:
University of Burgundy
Martin Luther University Halle-Wittenberg
Latest Pathology News
- AI Model Predicts Patient Response to Bladder Cancer Treatment
- New Laser-Based Method to Accelerate Cancer Diagnosis
- New AI Model Predicts Gene Variants’ Effects on Specific Diseases
- Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
- Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples
- 3D Cell Culture System Could Revolutionize Cancer Diagnostics
- Painless Technique Measures Glucose Concentrations in Solution and Tissue Via Sound Waves
- Skin-Based Test to Improve Diagnosis of Rare, Debilitating Neurodegenerative Disease
- Serum Uromodulin Could Indicate Acute Kidney Injury in COVID-19 Patients
- AI Model Reveals True Biological Age From Five Drops of Blood
- First-Of-Its-Kind AI Tool Visualizes Cell’s ‘Social Network’ To Treat Cancer
- New Test Diagnoses High-Risk Childhood Brain Tumors
- Informatics Solution Elevates Laboratory Efficiency and Patient Care
- Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread
- New AI Tool Outperforms Previous Methods for Identifying Colorectal Cancer from Tissue Sample Analysis
- New Technique Predicts Aggressive Tumors Before They Metastasize
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreMolecular Diagnostics
view channel
D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism
Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more
New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury
Drug-induced kidney injury, also known as nephrotoxicity, is a prevalent issue in clinical practice, occurring when specific medications at certain doses cause damage to the kidneys. Nephrotoxicity can... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read moreCerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
In recent years, cancer immunotherapy has emerged as a promising approach where the patient's immune system is harnessed to fight cancer. One form of immunotherapy, called CAR-T-cell therapy, involves... Read more
New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more
Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read moreMicrobiology
view channel
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read moreInnovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
Each year, 11 million people across the world die of sepsis out of which 1.3 million deaths are due to antibiotic-resistant bacteria. The burden of antimicrobial resistance (AMR) continues to weigh heavily,... Read more
Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
Acute infectious gastroenteritis results in approximately 179 million cases each year in the United States, leading to a significant number of outpatient visits and hospitalizations. To address this, a... Read moreTechnology
view channel
Smartphones Could Diagnose Diseases Using Infrared Scans
Rapid advancements in technology may soon make it possible for individuals to bypass invasive medical procedures by simply uploading a screenshot of their lab results from their phone directly to their doctor.... Read more
Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
Metabolites are critical compounds that fuel life's essential functions, playing a key role in producing energy, regulating cellular activities, and maintaining the balance of bodily systems.... Read more
3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
Microfluidic devices are diagnostic systems capable of analyzing small volumes of materials with precision and speed. These devices are used in a variety of applications, including cancer cell analysis,... Read moreIndustry
view channel
Tecan Acquires ELISA Immunoassay Assets from Revvity's Cisbio Bioassays
Tecan Group (Männedorf, Switzerland) has entered into an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS (Codolet, France), a subsidiary of the... Read more